Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Neuroendocrine gastro-entero-pancreatic tumors : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

[1]  J. Hainsworth,et al.  Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study , 2011, The Lancet.

[2]  B. King,et al.  Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. , 2009, Endocrine-related cancer.

[3]  D. Coppola,et al.  First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas , 2011, Cancer.

[4]  S. Willich,et al.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors , 2008, Cancer.

[5]  G. Åkerström,et al.  Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors , 2008, World Journal of Surgery.

[6]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[7]  R. Reznek,et al.  Imaging of neuroendocrine tumours (CT/MR/US). , 2007, Best practice & research. Clinical endocrinology & metabolism.

[8]  C. Nutting,et al.  Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients , 2008, American journal of clinical oncology.

[9]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. A. Sulbarán Muñoz,et al.  [Neuroendocrine neoplasms of the digestive system]. , 1990, G.E.N.

[11]  Thomas J Vogl,et al.  Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. , 2009, European journal of radiology.

[12]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[13]  B. Skogseid,et al.  Prognostic Factors and Survival in 324 Patients with Pancreatic Endocrine Tumor Treated at a Single Institution , 2008, Clinical Cancer Research.

[14]  G. Petersen,et al.  Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Hackshaw,et al.  Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours , 2010, British Journal of Cancer.

[16]  M. Stridsberg,et al.  Tumor Markers in Neuroendocrine Tumors , 2000, Digestion.

[17]  A. Sauvanet,et al.  [Surgical treatment of gastric, enteric pancreatic endocrine tumors. Part 2. treatment of hepatic metastases]. , 2005, Journal de chirurgie.

[18]  F. Que,et al.  Hepatic surgery for metastases from neuroendocrine tumors. , 2003, Surgical oncology clinics of North America.

[19]  Fynn Rw.  One hundred years after. , 1959 .

[20]  Metastatic Carcinoid Tumor: Changing Patterns of Care Over Two Decades , 2010, Journal of clinical gastroenterology.

[21]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Kaltsas,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations , 2008, Neuroendocrinology.

[24]  K. Oberg.  Interferon in the management of neuroendocrine GEP-tumors: a review. , 2000, Digestion.

[25]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[26]  R. Kianmanesh,et al.  Traitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques: 2. Traitement des métastases hépatiques , 2005 .

[27]  E. D. de Vries,et al.  Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Kjaer,et al.  F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors , 2010 .

[29]  G. Åkerström,et al.  Surgery on neuroendocrine tumours. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[30]  L. Kvols,et al.  Original article DOI: 10.1093/annonc/mdh216 , 2003 .

[31]  M. Milas,et al.  Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. , 2007, Surgery.

[32]  S. Knappskog,et al.  Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy , 2011, Cancer.

[33]  I. Modlin,et al.  article : somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine ( carcinoid ) tumours , 2009 .